Publically available external pharmacovigilance databases, such as the American FDA’s Adverse Event Reporting System (AERS) and the VigiBase database of the Uppsala Monitoring Centre (UMC), are currently not obligatorily taken into account by the pharmaceutical product manufacturers regarding potential drug safety signals. The value of this information on adverse events that is revealed in these databases is well acknowledged by product experts. These external data sources are now being evaluated for their suitability to at least support signal verification for signals which have been detected within a pharmaceutical company. The appropriate software tools needed to support the integration of this information into the commonly used statistical methods of signal detection have been developed. In his study, Denny Lorenz evaluates the benefit of the reports that the market leading software ‘Empirica Signal’ generates for common questions during the signal verification process. The major external databases and statistical methods are described and structurally assessed. Besides the selection of reports, contrary opinions on the hierarchy levels of drug and event on which the statistical scores are calculated, are discussed. The study demonstrates that the decision on these levels and the depths of the external analyses itself is a trade-off between scientific ambitions and the limits of time and money that companies are willing to invest in this endeavor.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Denny Lorenz, born in 1982, studied business informatics at the Berlin School of Economics (University of Applied Science) from 2002 to 2005 and Consumer Health Care at the Charité Universitätsmedizin Berlin from 2009 to 2011. Currently the author is working for the pharmacovigilance department of one of the leading German research-based pharmaceutical companies.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 34950677
Anzahl: 2 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 34950677-n
Anzahl: 2 verfügbar
Anbieter: PBShop.store US, Wood Dale, IL, USA
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers GZ-9783838204321
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers GZ-9783838204321
Anzahl: 1 verfügbar
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Zustand: New. Bestandsnummer des Verkäufers V9783838204321
Anzahl: 1 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 34950677-n
Anzahl: 2 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Bestandsnummer des Verkäufers V9783838204321
Anzahl: 1 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 34950677
Anzahl: 2 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Publically available external pharmacovigilance databases, such as the American FDA s Adverse Event Reporting System (AERS) and the VigiBase database of the Uppsala Monitoring Centre (UMC), are currently not obligatorily taken into account by the pharmaceutical product manufacturers regarding potential drug safety signals. The value of this information on adverse events that is revealed in these databases is well acknowledged by product experts. These external data sources are now being evaluated for their suitability to at least support signal verification for signals which have been detected within a pharmaceutical company. The appropriate software tools needed to support the integration of this information into the commonly used statistical methods of signal detection have been developed. In his study, Denny Lorenz evaluates the benefit of the reports that the market leading software Empirica Signal generates for common questions during the signal verification process. The major external databases and statistical methods are described and structurally assessed. Besides the selection of reports, contrary opinions on the hierarchy levels of drug and event on which the statistical scores are calculated, are discussed. The study demonstrates that the decision on these levels and the depths of the external analyses itself is a trade-off between scientific ambitions and the limits of time and money that companies are willing to invest in this endeavor. 146 pp. Englisch. Bestandsnummer des Verkäufers 9783838204321
Anzahl: 2 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. Print on Demand pp. 146. Bestandsnummer des Verkäufers 383898083
Anzahl: 4 verfügbar